Linked Life Data

2949974

Source:http://linkedlifedata.com/resource/pubmed/id/2949974

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1987-4-13
pubmed:abstractText
Coronary blood flow might be reduced by platelet aggregates or by vasospasm induced by platelet-produced thromboxane A2. Therefore the effects of the platelet inhibitor ticlopidine (500 mg daily) on platelet function and on exercise tolerance were investigated in a double-blind placebo-controlled study in 38 middle-aged men with stable incapacitating angina pectoris. Before and after 4 and 8 weeks of treatment, exercise tests were performed in warm and cold environments. The in vitro platelet reactivity to ADP was determined at rest and the plasma levels of beta-thromboglobulin (BTG) and platelet factor 4 (PF4) were measured before and immediately after exercise. There were no signs of increased platelet activity at rest or after exercise as judged by the levels of BTG and PF4. Despite a potent inhibition of platelet reactivity to ADP in vitro during ticlopidine treatment, the exercise tolerance was reduced in exercise tests in both warm and cold environments and in daily life. Therefore platelet activity does not seem to play any significant role in exercise tolerance in the stable phase of angina pectoris.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0195-668X
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
25-30
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:year
1987
pubmed:articleTitle
Effects of the platelet inhibitor ticlopidine on exercise tolerance in stable angina pectoris.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial, Research Support, Non-U.S. Gov't